McKesson Corporation vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? McKesson Corporation trades at $937.1 (market cap $108.46B), while Direxion Daily FTSE China Bull 3x Shares trades at $25.3 (market cap $560.32M). The key difference: McKesson Corporation is far larger — about 193.6× Direxion Daily FTSE China Bull 3x Shares's market cap, and McKesson Corporation pays a 0.4% dividend while Direxion Daily FTSE China Bull 3x Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Direxion Daily FTSE China Bull 3x Shares for 25 Days on average.
| MCK | YINN | |
|---|---|---|
Market Cap | $108.46B | $560.32M |
Volume | 712,607 | 1,009,521 |
Sector | Health | Leveraged / Inverse |
52-Week High | $995.69 | $52.69 |
52-Week Low | $725.17 | $21.45 |
Typical Hold Time | 74 Days | 25 Days |
Enterprise Value | $115.00B | — |
Dividend Yield | 0.4% | — |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $937.98, up 3.04% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent positive developments include the CVS Health partnership extension through 2032 and raised full-year guidance. Revenue growth remains robust at $359.05 billion for 2025, though net margins are thin at 1.12%.
The outlook remains positive with 81% analyst buy ratings and a $956.43 consensus target. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. Strong cash flow generation ($6.09B operating cash flow) supports the dividend and growth initiatives, while technical indicators show the stock testing resistance near $938.
YINN trades at $25.17, up 6.83% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock lacks fundamental financial data disclosure, with key valuation and profitability ratios unavailable. Recent news highlights China's economic policies and export controls, which may influence the fund's underlying holdings.
The outlook is cautious due to bearish technicals and opaque fundamentals. Risks include exposure to Chinese market volatility and regulatory changes. Analyst sentiment is not clearly defined without current consensus data, requiring careful monitoring of emerging financial disclosures and geopolitical developments.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →